The findings come from the first and only decentralized real-world study examining how HD chorea affects patients and caregivers and how treatment impacts quality of life
Approval makes it the first and only therapy in the EU indicated for both acute and chronic hepatitis C, supported by Phase 3 data
Partnership combines Apexon's agentic AI platforms and cloud modernization tools with AWS infrastructure to accelerate AI deployment, clinical innovation, and digital transformation across healthcare and life sciences
The filing is backed by positive Phase 3 results recently published in JAMA Neurology
The incubator anchored at the company's global headquarters in Raleighla launches alongside an inaugural partnership with Cape Fear BioCapital, a Durham-based seed-stage venture capital firm
Initiative seeks innovative experimental and computational approaches to uncover neural circuits regulating immune function and identify novel therapeutic targets
The company plans an aggressive partnering push, with 62 pre-scheduled meetings over four days, focused on out-licensing, co-development, and strategic collaborations with global pharmaceutical and biotech players
Pharma powerhouse names Cecile Guegan interim finance chief
Bolstering neuroscience push with late-stage Tourette therapy
Researchers emphasized that the benefit persisted well beyond the treatment period, reinforcing the clinical rationale for time-limited therapy in selected patients
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
